Progress in Nanomedicine in Neurologic Diseases

This book covers the use of nanomedicine in the delivery of neuroprotective agents, including pharmacological drugs, stem cells, neurotrophic factors, monoclonal antibodies and enzymes to induce greater beneficial effects in neurologic diseases. Thus, the main purpose of the book is to explore the delivery of drugs either alone or in combination with stem cells to enhance neuroprotection in neurological diseases. Brain pathology associated with acute trauma such as head injury and brain blast injury can also be managed using novel treatment strategies. In addition, emphasis is made that standard patterns of brain pathology may be complicated with multiple comorbidity factors where one agent alone is not sufficient to induce brain protection. Enzymes and antibodies may help in combination and enhance the efficacy when administered through nanotechnology. Progress in Nanomedicine in Neurologic Diseases will encourage further research in the field of neuroprotection, brain injury, neurodegenerative diseases, neuropharmacology, neuropathology, and neurology. Students and researchers along with policy makers, teachers and health care professionals may also benefit from the findings of the book for enhanced patients care.

Explores the nanodelivery of neuroprotective agents in neurologic diseases Furthers the awareness of the importance of comorbidities in neurologic diseases Presents detailed coverage of nanowires for delivery of neuroprotective agents

Auteur

Hari S. Sharma, PhD, is Professor of Neurobiology, Department of Surgical Sciences, Anesthesiology and Intensive Care at Uppsala University, Uppsala, Sweden Aruna Sharma, MD, is in the Department of Surgical Sciences, Anesthesiology and Intensive Care at Uppsala University, Uppsala, Sweden

Contenu

Section I: Neurodegenerative diseases.- Chapter 1 : Nanowired delivery of cerebrolysin together with antibodies to amyloid beta peptide, phosphorylated tau and tumor necrosis factor alpha induces superior neuroprotection in Alzheimer's disease brain pathology exacerbated by sleep deprivation.- Chapter 2 : Nanodelivery of histamine H3/H4 receptor modulators BF2649 and clobenpropit with antibodies to amyloid beta peptide in combination with alpha synuclein reduces brain pathology in Parkinson's disease.- Chapter 3 : Co-administration of nanowired DL-3-n-butylphthalide (DL-NBP) together with mesenchymal stem cells, monoclonal antibodies to alpha synuclein and TDP-43 (TAR DNA-binding protein 43) enhance superior neuroprotection in Parkinson's disease following concussive head injury.- Chapter 4: Neuroprotective effects of nanowired delivery of cerebrolysin with mesenchymal stem cells and monoclonal antibodies to neuronal nitric oxide synthasein brain pathology following Alzheimer's disease exacerbated by concussive head injury.- Section II: Central Nervous system Trauma.- Chapter 5: Co-administration of nanowired monoclonal antibodies to inducible nitric oxide synthase and tumor necrosis factor-alpha together with antioxidant H-290/51 reduces SiO2-nanoparticles induced exacerbation of pathophysiology of spinal cord trauma.- Chapter 6: Nanowired delivery of cerebrolysin with mesenchymal stem cells attenuates heat stress induced exacerbation of neuropathology following brain blast injury.- Chapter 7: Co-administration of nanowired oxiracetam and neprilysin with monoclonal antibodies to amyloid beta peptide and p-tau thwarted exacerbation of brain pathology in concussive head injury at hot environment.- Section III. Stress and Drugs of abuse.- Chapter 8: Nanowired delivery of mesenchymal stem cells with antioxidant compound H-290/51 reduces exacerbation of methamphetamine neurotoxicity in hot environment.- Chapter 9: TiO2-nanowired delivery of Chinese extract of Gingko biloba EGb-761 and bilobalide BN-52021 enhanced neuroprotective effects of cerebrolysin following spinal cord injury at cold environment.- Chapter 10: Nanowired delivery of curcumin attenuates methamphetamine neurotoxicity and elevates levels of dopamine and brain derived neurotrophic factor.